Enjoy complimentary customisation on priority with our Enterprise License!
The Global Alzheimers Disease Therapeutics Market size is estimated to grow by USD 5.41 billion at a CAGR of 10.03% between 2023 and 2028.
There has been an increasing awareness regarding Alzheimer's disease across the world. In addition, there are several initiatives to increase community awareness about Alzheimers disease. For instance, the funded projects provided evidence-based and evidence-informed interventions and conducted extensive education, training, and outreach programs in various US communities. Moreover, there are several other Alzheimer's programs and public initiatives, such as the National Alzheimers Plan, AFA Teens, The Alzheimers Association Walk to End Alzheimers, and The Hampden Good Neighbor Program in the US. Hence, such factors are positively impacting the market.
Technavio has segmented the market into Distribution Channel, Drug Class, and Geography
It also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historical data from 2018 - 2022, besides analyzing the current market scenario.
To learn more about this report, Request Free Sample
The hospital pharmacy segment is estimated to witness significant growth during the forecast period. This segment is considered as the major distribution channel for Alzheimer's disease therapeutics owing to the large-scale requirements of such drugs for the treatment of patients. In addition, the increasing investment by the governments of several countries, such as India and China, to improve healthcare infrastructure will fuel the growth of this segment.
Get a glance at the market contribution of various segments Download PDF Sample
The hospital pharmacy segment was the largest segment and was valued at USD 3.55 billion in 2018. Moreover, the rapid growth in the number of hospitals in developing countries such as India and the rise in government initiatives to develop healthcare infrastructure has increased the demand for Alzheimer's disease therapeutics. Therefore, the demand for Alzheimer's disease therapeutics in hospitals is also increasing. In addition, the increasing number of cases of Alzheimer's disease will likely increase the adoption of Alzheimers disease therapeutics in hospitals worldwide. Hence such factors are expected to propel the hospital segment, which is expected to fuel the growth of the hospital pharmacy segment of the market during the forecast period.
The cholinesterase segment is an important therapeutic target for Alzheimer's disease. In addition, the deterioration of cholinergic neurons in the brain and the loss of neurotransmission are the major causes of the decline in cognitive functions in patients with Alzheimer's disease. Moreover, the main cause of Alzheimer's disease is also a reduction in acetylcholine synthesis. Hence, one of the possible therapeutic strategies is to increase the cholinergic levels in the brain by inhibiting the biological activity of acetylcholinesterase. Furthermore, as cholinesterase inhibitors increase the availability of acetylcholine in central synapses, it has now become the main approach to the symptomatic treatment of Alzheimer's disease. Hence, such factors are fuelling the growth of this segment which in turn drives the market growth during the forecast period.
One of the only approved N-methyl-D-aspartate receptor antagonists for the symptomatic treatment of moderate-to-severe Alzheimer's disease is Memantine. In addition, it possesses a three-ring structure with a bridgehead amine. Under physiological conditions, it carries a positive charge that binds at the Mg2+ site within the N-methyl-D-aspartate receptor-associated channel. Moreover, according to clinical trial results, memantine can achieve its pharmacological actions and does not show the adverse effects typically associated with high-affinity NMDA blockers. Furthermore, memantine has exhibited efficacy and safety in placebo-controlled trials in patients with moderate-to-severe Alzheimer's disease. Hence, such factors are fuelling the growth of this segment which in turn drives the market growth during the forecast period.
For more insights about the market share of various regions Download PDF Sample now!
North America is estimated to contribute 39% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. North America holds the major share of the global Alzheimers disease therapeutics market, primarily due to the increasing awareness of the disease and its strong prevalence of Alzheimer's disease. In addition, the prevalence of the disease has been increasing at a significant rate in the developed countries of the region. Moreover, the prevalence of Alzheimer's disease and other dementias is also high in Canada. For instance, In 2011, 2.23% of the total population of Canada was affected by Alzheimer's disease and other dementias. In addition, this percentage is expected to increase to 3.45% by 2031. Hence, such factors are driving the market growth in North America during the forecast period.
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:
AB Science SA: The company offers alzheimer disease therapeutics such as Masitinib.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
There are multiple factors influencing market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges.
One of the key factors driving the Alzheimer's disease therapeutics market growth is the availability, research, and development of novel biomarkers. Alzheimer's disease can be referred to as a neurodegenerative disorder characterized by the formation of B-amyloid plaques and neurofibrillary masses in the brain parenchyma, which causes synapse and neuronal loss and leads to progressive memory loss in individuals. In addition, the prevalence of Alzheimer's disease has increased globally.
As a result, developing new therapies to treat patients with Alzheimer's disease has become critically important. This can be achieved by identifying disease-modifying therapies and testing them in clinical trials. In addition, biomarkers play an important role in Alzheimer's disease therapeutics drug development. Furthermore, in Alzheimer's disease, biomarkers are tests of bodily fluids, including blood and cerebral spinal fluid, as well as neuroimaging scans such as positron emission tomography (PET) and magnetic resonance imaging (MRI). Hence, such developments are driving the market growth during the forecast period.
A key factor shaping the Alzheimer's disease therapeutics market growth is the increasing funding for therapeutics discovery. The rising prevalence of Alzheimer's disease has led to an increase in demand for its therapeutics, as well as garnered significant funding for the development of therapeutics. In addition, over the past years, different organizations and governments globally have been investing in therapeutics for Alzheimer's disease, which has resulted in scientific achievements that have benefited many people with Alzheimer's disease globally.
Moreover, the Federal Government of the US is the largest public funder of research and development of therapeutics for Alzheimer's disease. In addition, organizations such as The National Institute on Aging, the National Center for Advancing Translational Science, the National Institute of General Medical Sciences, and the National Institute of Mental Health grant funds for research on drug development for Alzheimer's disease. Hence, such factors are driving the market growth during the forecast period.
Issues associated with the diagnosis of Alzheimer's disease are one of the key challenges hindering the Alzheimer's disease therapeutics market growth. It is still a clinical challenge to determine Alzheimer's disease at an early stage. In addition, the neuropathological changes in Alzheimer's disease start to accumulate in the brain 10-15 years before the first sign of clinical impairment.
Moreover, dementia due to Alzheimer's disease is the last stage of the disease. In addition, the major limitation of the current approaches is that the number of useful markers for every stage of the disease is less. Furthermore, markers for brain atrophy have been developed, but the condition is not always present at the early diagnosis of Alzheimer's disease. Hence, such factors are hindering the market growth during the forecast period.
The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Alzheimer's Disease Therapeutics Market Customer Landscape
The Alzheimer's disease therapeutics market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2018 to 2028.
Alzheimer's Disease Therapeutics Market Scope |
|
Report Coverage |
Details |
Page number |
168 |
Base year |
2023 |
Historic period |
2018-2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 10.03% |
Market Growth 2024-2028 |
USD 5.41 billion |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
8.83 |
Regional analysis |
North America, Europe, Asia, and the Rest of the World (ROW) |
Performing market contribution |
North America at 39% |
Key countries |
US, Canada, UK, Germany, and Japan |
Competitive landscape |
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
Key companies profiled |
AB Science SA, AbbVie Inc., AgeneBio Inc., Biogen Inc., Cipla Ltd., Curasia Medilab, Denali Therapeutics Inc., Eisai Co. Ltd., Eli Lilly and Co., Grifols SA, H Lundbeck AS, Johnson and Johnson, Lifecare Neuro Products Ltd., Lupin Ltd., Novartis AG, Pfizer Inc., Psycogen Captab, Solco Healthcare, Teva Pharmaceutical Industries Ltd., and Aurobindo Pharma Ltd. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Download Sample PDF at your Fingertips
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.